Clinical Trial Detail

NCT ID NCT03382912
Title Study of AM0010 With NivolumabStudy of AM0010 With Nivolumab Compared to Nivolumab Alone Second-line Tx in Patients With Metastatic Non-Small Cell Lung Cancer (Cypress 2)
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors ARMO BioSciences
Indications

lung non-small cell carcinoma

Therapies

Nivolumab + Pegilodecakin

Nivolumab

Age Groups: adult senior

Additional content available in CKB BOOST